Metraipolis › archive › dc_77ff58726fbb

De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report — Europe PMC PMID:41589251

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41589251
DOI: 10.1007/s13691-[numero omesso]-2
License (as archived): solo-consultazione
Archived: 2026-11-07T17:04:49.598Z
SHA-256 of the archived text: d895e62f2fa8d2d7341cca01356e66b4a4ab7c08f13e42c4118cfb359fd59f66
Stable URL of this page: https://metraipolis.com/documento/dc_77ff58726fbb

How to cite

De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report — Europe PMC PMID:41589251 — Europe PMC (en), https://europepmc.org/article/MED/41589251 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_77ff58726fbb (Metraipolis archive dc_77ff58726fbb, sha256 d895e62f2fa8d2d7341cca01356e66b4a4ab7c08f13e42c4118cfb359fd59f66)

BibTeX

@misc{dc77ff58726fbb,
  title = {De Novo high-volume metastatic prostate cancer with primary resistance to standard systemic therapy and exceptional response to PSMA-Lu177: A case report — Europe PMC PMID:41589251},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41589251},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_77ff58726fbb; sha256 d895e62f2fa8d2d7341cca01356e66b4a4ab7c08f13e42c4118cfb359fd59f66},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41589251. Agents can read the archived copy with the MCP tool read_document.